Long intergenic noncoding RNA 299 methylation in peripheral blood is a biomarker for triple-negative breast cancer. (13th September 2018)

• Record Type: Journal Article
• Authors: Bermejo, Justo L; Huang, Guanmengqian; Manoochehri, Mehdi; Mesa, Karen G; Schick, Matthias; Silos, Rosa G; Ko, Yon-Dschun; Brüning, Thomas; Brauch, Hiltrud; Lo, Wing-Yee; Hoheisel, Jörg D; Hamann, Ute
• Is Part Of: Epigenomics. Volume 11:Number 1(2019)
• Page Start: 1711
• Page End: 1723
• Publication Date: 2018-09-13
• Subjects: blood DNA methylation -- epigenetic modification -- epigenome-wide association study -- risk biomarker -- triple-negative breast cancer; Epigenesis -- Periodicals; Genomics -- Periodicals; Chromatin -- Periodicals; DNA -- Periodicals; 572.87
• DOI: 10.2217/epi-2018-0121
• Languages: English
• ISSNs: 1750-1911

Abstract

Aim: To identify DNA methylation biomarkers in peripheral blood samples from triple-negative breast cancer (TNBC) patients.Materials & methods: We conducted an epigenome-wide association study (EWAS): the most promising markers were identified in 233 TNBC case–control pairs (discovery set) and subsequently validated in an independent validation set (57 TNBC patients and 124 controls).Results: cg06588802 ( LINC00299/ID2 ) showed a higher methylation in TNBC patients compared with controls (discovery set: 3% increase, p-value = 0.0009; validation set: 2% increase, p-value = 0.01). Consistent results at four neighboring methylation probes and the strong negative correlation (rho = -0.93) with LINC00299 expression add plausibility to this result.Conclusion: Hypermethylation of LINC00299 in peripheral blood may constitute a useful circulating biomarker for TNBC.